Last reviewed · How we verify
AZTREONAM LYSINE
AZTREONAM LYSINE is a drug. It is currently FDA-approved (first approved 2009).
Aztreonam lysine is a marketed antibiotic with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from other antibiotics in the market. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | AZTREONAM LYSINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
Common side effects
Key clinical trials
- Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis (PHASE4)
- Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
- Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis
- Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) (PHASE4)
- Aztreonam Lysine for Pseudomonas Infection Eradication Study (PHASE2)
- Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection (PHASE3)
- Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZTREONAM LYSINE CI brief — competitive landscape report
- AZTREONAM LYSINE updates RSS · CI watch RSS
Frequently asked questions about AZTREONAM LYSINE
What is AZTREONAM LYSINE?
AZTREONAM LYSINE is a Small molecule drug.
When was AZTREONAM LYSINE approved?
AZTREONAM LYSINE was first approved on 2009.
What development phase is AZTREONAM LYSINE in?
AZTREONAM LYSINE is FDA-approved (marketed).
Related
- Compare: AZTREONAM LYSINE vs similar drugs
- Pricing: AZTREONAM LYSINE cost, discount & access